Article
Riding on rosy estimates of Zolgensma sales, RegenxBio sells part of its royalty for $200M
Rating:
0.0
Views:
72
Likes:
1
Library:
1
RegenxBio's journey as a drug developer may have been less than rosy, but there's been little doubt about the value of the gene therapy technology it obtained from Jim Wilson's labs. Healthcare Royalty Management has made that clear once again, striking a deal to buy a portion of its royalties
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value